Literature DB >> 19710031

Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study.

Karam S Boparai1, Elisabeth M H Mathus-Vliegen, Jan J Koornstra, Fokko M Nagengast, Monique van Leerdam, Carel J M van Noesel, Martin Houben, Annemieke Cats, Liselotte P van Hest, Paul Fockens, Evelien Dekker.   

Abstract

BACKGROUND AND AIMS: Patients with hyperplastic polyposis syndrome (HPS) receive endoscopic surveillance to prevent malignant progression of polyps. However, the optimal treatment and surveillance protocol for these patients is unknown. The aim of this study was to describe the clinical and pathological features of a large HPS cohort during multiple years of endoscopic surveillance.
METHODS: Databases were searched for patients with HPS, who were analysed retrospectively. Endoscopy reports and histopathology reports were collected to evaluate frequency of endoscopic surveillance and to obtain information regarding polyp and the presence of colorectal cancer (CRC).
RESULTS: In 77 patients with HPS, 1984 polyps were identified during a mean follow-up period of 5.6 years (range: 0.5-26.6). In 27 (35%) patients CRC was detected of which 22 (28.5%) at initial endoscopy. CRC was detected during surveillance in five patients (cumulative incidence: 6.5%) after a median follow-up time of 1.3 years and a median interval of 11 months. Of these interval CRCs, 4/5 were detected in diminutive serrated polyps (range: 4-16 mm). The cumulative risk of CRC under surveillance was 7% at 5 years. At multivariate logistic regression, an increasing number of hyperplastic polyps (OR 1.05, p=0.013) and serrated adenomas (OR 1.09, p=0.048) was significantly associated with CRC presence.
CONCLUSIONS: HPS patients undergoing endoscopic surveillance have an increased CRC risk. The number of serrated polyps is positively correlated with the presence of CRC in HPS, thus supporting a 'serrated pathway' to CRC. To prevent malignant progression, adequate detection and removal of all polyps seems advisable. If this is not feasible, surgical resection should be considered.

Entities:  

Mesh:

Year:  2009        PMID: 19710031     DOI: 10.1136/gut.2009.185884

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  57 in total

1.  Risk factors: Hyperplastic polyposis syndrome and risk of colorectal cancer.

Authors:  Joanne P Young; Susan Parry
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11       Impact factor: 46.802

Review 2.  Familial colorectal cancer, beyond Lynch syndrome.

Authors:  Elena M Stoffel; Fay Kastrinos
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-17       Impact factor: 11.382

Review 3.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

4.  Serrated polyposis: the problem of definition and its relationship to the population at risk for syndrome-related colorectal cancer.

Authors:  Joanne P Young; Timothy J Price; Susan Parry
Journal:  Transl Cancer Res       Date:  2017-12       Impact factor: 1.241

Review 5.  Colorectal cancer diagnosis in 2012: A new focus for CRC prevention--more serration, less inflammation.

Authors:  James E East; Evelien Dekker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

6.  Adenoma detection in excellent versus good bowel preparation for colonoscopy.

Authors:  Danielle M Tholey; Corbett E Shelton; Gloria Francis; Archana Anantharaman; Robert A Frankel; Paurush Shah; Amy Coan; Sarah E Hegarty; Benjamin E Leiby; David M Kastenberg
Journal:  J Clin Gastroenterol       Date:  2015-04       Impact factor: 3.062

Review 7.  Diagnosis, epidemiology and management of serrated polyposis syndrome: a comprehensive review of the literature.

Authors:  Fotios S Fousekis; Ioannis V Mitselos; Dimitrios K Christodoulou
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

8.  Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study.

Authors:  Daniel D Buchanan; Kevin Sweet; Musa Drini; Mark A Jenkins; Aung Ko Win; Michael Gattas; Michael D Walsh; Mark Clendenning; Diane McKeone; Rhiannon Walters; Aedan Roberts; Alasdair Young; Heather Hampel; John L Hopper; Jack Goldblatt; Jill George; Graeme K Suthers; Kerry Phillips; Graeme P Young; Elizabeth Chow; Susan Parry; Sonja Woodall; Kathy Tucker; Amanda Muir; Michael Field; Sian Greening; Steven Gallinger; Jane Green; Michael O Woods; Renee Spaetgens; Albert de la Chapelle; Finlay Macrae; Neal I Walker; Jeremy R Jass; Joanne P Young
Journal:  Int J Colorectal Dis       Date:  2010-03-06       Impact factor: 2.571

9.  Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics.

Authors:  Daniel D Buchanan; Kevin Sweet; Musa Drini; Mark A Jenkins; Aung Ko Win; Dallas R English; Michael D Walsh; Mark Clendenning; Diane M McKeone; Rhiannon J Walters; Aedan Roberts; Sally-Ann Pearson; Erika Pavluk; John L Hopper; Michael R Gattas; Jack Goldblatt; Jill George; Graeme K Suthers; Kerry D Phillips; Sonja Woodall; Julie Arnold; Kathy Tucker; Amanda Muir; Michael Field; Sian Greening; Steven Gallinger; Renee Perrier; John A Baron; John D Potter; Robert Haile; Wendy Frankel; Albert de la Chapelle; Finlay Macrae; Christophe Rosty; Neal I Walker; Susan Parry; Joanne P Young
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

10.  Extracolonic cancer risk in patients with serrated polyposis syndrome and their first-degree relatives.

Authors:  Yark Hazewinkel; Johannes B Reitsma; Fokko M Nagengast; Hans F Vasen; Theo A M van Os; Monique E van Leerdam; Jan-Jacob Koornstra; Evelien Dekker
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.